ASAHI INTECC CO., LTD. Is the world leader in the production of coronary conductors and devices for overcoming chronic occlusions. The company was founded in 1972, under the name of Asahi Mini Rope Co., Ltd. in Japan, as a manufacturer of ultra-thin steel wire braiding and conductor materials. Since 1988 the company is called ASAHI INTECC CO., LTD.
At this moment, ASAHI INTECC CO., LTD. has production sites in Japan, Thailand, Vietnam, as well as a distribution network around the world. Not stopping at the achieved, the company ASAHI INTECC CO., LTD. does not stop the development of new high-quality products and, at the moment, produces: coronary conductors, peripheral conductors, microconductors, microcatheters, guiding catheters and other products.
Super selective microcatheter to achieve distally located targets.
The company Eucatech AG (Rheinfelden, Germany) was founded in 1997, today has an extensive distribution network in more than 30 countries. Mostly Eucatech AG specializes in vascular interventional cardiology and radiology. Among the main products of this company you will find balloon catheters, stents, stenting systems, multi-purpose catheters, drug-coated stents, stenting systems with medicated coating, as well as a unique Comouflage® coating process
Goodman Co., Ltd. - a private Japanese company, established in 1975. Started its activities as an importer and distributor (since 1981) of medical equipment and medical products. However, in 1984 she organized her own production of medical devices for minimally invasive intravascular operations. Goodman Co., Ltd. includes or entered such well-known enterprises as Cosmo Co. Ltd., LightLab Imaging Inc. (later it was sold to St. Jude Medical), Intella Interventional Systems Inc., Avantec Vascular Corp. Currently Goodman Co., Ltd. has production sites in Japan, the United States and Ireland. Goodman Co., Ltd. This is an uncompromising Japanese quality and perfection of technical solutions. All products of the company are authorized for use in Japan and Western Europe. All products of Goodman Co., Ltd. registered and authorized for use in Belarus and Russia.
Assomedica Ltd Co is the exclusive distributor of Goodman Co., Ltd. in Russia, Belarus and Kazakhstan.
Acist Medical System is the world leader in the production of contrast systems for angiography. It was the company Acist Medical Systems that introduced the concept of "variable flow" into the process of X-ray endovascular interventions, which allowed replacing the manual introduction of contrast in coronary angiography, using an automatic injector. This made coronary angiography much safer and more effective, allowed to reduce the dose of contrast administered and, as a consequence, reduced the likelihood of development of contrast-induced nephropathy.
The company Acist Medical Systems was founded in 1991 and now more than 10 million procedures are performed worldwide with the help of Acist CVi inverters.
Automated Impella® Controller
Acute heart failure and true cardiogenic shock, as its extreme degree, are the most dangerous complications of myocardial infarction. The cause of acute heart failure is a progressive decrease in the pump function of the ventricular myocardium due to the violation of coronary blood flow and oxygen supply.
- The incidence of acute heart failure is an average of 1 per 10 000 population per year, with a mortality rate of 60-80%.
- The only effective method of treatment is the fastest recovery of coronary blood flow (reperfusion) against the background of the use of effective auxiliary circulation.
Performing PTCA in complex coronary artery lesions (LCA trunk, multifocal lesion, etc.) in patients with multiple concomitant pathologies, including the presence of severe chronic heart failure, is a complex task, associated with a high risk of intraoperative and postoperative complications.
- The use of the Impella auxiliary circulation system with the Impella 2.5 catheter pump in such cases can prevent hemodynamic destabilization associated with recurring episodes of reversible myocardial ischemia and a sharp decrease in blood pressure that occur with temporary occlusion of the coronary arteries with angioplasty instruments.
The assisted circulation technology of Impella is based on the direct catheterization of the cavities of the ventricles of the heart and the pumping of blood into the central vessels along the shortest (anatomical) pathway with the help of miniature axial blood pumps built into the cannula with an inlet and an outlet for blood.
This excludes the outer contour of the auxiliary circulation, consisting of cannulas, trojuses, filters and other components, requiring filling (priming) with the patient's blood, reducing BCC and provoking an immune-inflammatory response from the blood.
- The design of Impella catheter pumps allows them to be installed within minutes through a puncture or incision of peripheral arteries in conditions of an angiographic room.
- The use of the circulatory system Impella® does not require cardiosurgical support.
- The use of the assisted circulation system of Impella® has a very low risk of thromboembolic, infectious complications and hemolysis.
- The use of the assisted circulation system of Impella® suggests a simple and liberal regimen of anticoagulant therapy.
- The Impella auxiliary circulation system with Impella catheter pumps provides direct hemodynamic discharge of the ventricular myocardium.
The effectiveness and safety of the system is proved by a number of clinical studies, including randomized ones.
Straub Medical AG is the world leader in the manufacture of systems for mechanical intravascular thrombectomy.
The idea of mechanical intravascular thrombectomy was born in the early 90s. In 1995, a patent of the Rotarex system was obtained. In 1999, the system received CE Mark for the Rotarex system. In 2004-2005, the Aspirex system was patented and received the CE Mark system.
Currently, the company produces and exports products to more than 50 countries. Straub Medical AG does not stop the development of new products and the improvement of existing models, the emphasis is on improving efficiency, safety, as well as reducing the time of the operation.
The company Stentys S.A. was founded in 2006 for the development and production of coronary stents with the property of adaptive apposition - Self-Aporing ® Stent System
These stents are able to change the diameter after installation without the need for balloon post-dilatation, which facilitates the correct choice of the stent size for myocardial infarction and for certain anatomical characteristics of the affected area - the left coronary artery trunk, bifurcations, ectatic artery transformation, and other recalibration options.
The program of clinical trials, in which more than 2,500 patients participated, demonstrated excellent angiographic and long-term results of stenting, as well as high safety of stents with adaptive apposition by Stentys S.A.
Stents with adaptive apposition simplify the choice of stent size for myocardial infarction
Founded in 1987 in the United States and rightfully considered a world leader, Merit Medical Systems Inc. produces various devices that are used in diagnostic and intervention interventions on coronary and peripheral vessels, as well as in other non-vascular diseases